Gene-modified coxsackievirus
AssigneesShin Nihon Seiyaku Co., Ltd, Kyushu University, National University Corporation
InventorsKenzaburo Tani, Shohei Miyamoto, Hiroyuki Inoue, Miyako Sagara
Life of this patent
Estimating the term…
Abstract
A modified coxsackievirus showing improved safety and/or aggressiveness to be used for oncolytic virotherapy is provided. A modified coxsackievirus showing tissue-specific suppression of proliferation and comprising a mutated genome consisting of the genome of coxsackievirus B3 wild-type (CVB3-WT) inserted with at least one polynucleotide consisting of a target sequence of tissue-specific microRNA (miRNA) is provided. The mutated genome is preferably further inserted with the region encoding GM-CSF in an expressible form.
Claims17
A modified coxsackievirus of which proliferation is suppressed in a tissue-specific manner, which comprises a mutated genome corresponding to genome of coxsackievirus B3 wild-type (CVB3-WT) inserted with at least one polynucleotide consisting of a target sequence of a tissue-specific microRNA (miRNA),
- wherein the inserted polynucleotide is the polynucleotide of the following sequence of (a) or (b):
- (a)
- ATA CAT ACT TCT TTA CAT TCC Acg atA TAC ATA
- CTT CTT TAC ATT CCA acc ggt TCC AAT CAG TTC
- CTG ATG CAG TAt cac TCC AAT CAG TTC CTG ATG
- CAG TA which is SEQ ID NO:
- 1;
- or
- (b)
- TCC AAT CAG TTC CTG ATG CAG TAc gat TCC AAT
- CAG TTC CTG ATG CAG TAa ccg gtT CCA ATC AGT
- TCC TGA TGC AGT Atc acT CCA ATC AGT TCC TGA
- TGC AGT A which is SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.